I alt 136, 21 og 82 patienter fik mindst én ublindet dosis i henholdsvis forsøg 301, 301EXT og 302EXT.
A total of 136, 21, and 82 patients received at least one open-label dose in studies 301, 301EXT, and 302EXT, respectively.